Risk factors for infection in Malaysian patients with systemic lupus erythematosus

QJM: An International Journal of Medicine

Volumn 89, Issue 7, 1996, Pages 531-538

  Paton, N I J ^a,b   Cheong, I K S ^a   Kong, N C T ^a   Segasothy, M ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE;

ADOLESCENT; ADULT; ARTICLE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALAYSIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0030016586     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/89.7.531     Document Type: Article

References (14)

1. Ginzler E, Berg A. Mortality in Systemic Lupus Erythematosus. J Rheumatol 1987; 14(suppl 13):218-22.
2. Staples PJ, Gerding DN, Decker JL, Gordon RS Jr. Incidence of infection in systemic lupus erythematosus. Arthritis Rheum 1974; 17:1-10.
3. Ginzler E, Diamond H, Kaplan D, Weiner M, Schlesinger M, Seleznick M. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 1978; 21:37-44.
4. Lee P, Urowitz MB, Bookman AAM, Koehler BE, Smythe HA, Gordon DA, Ogryzlo MA. Systemic lupus erythematosus. A review of 110 cases with reference to nephritis, the nervous system, infections, aseptic necrosis, and prognosis. Q J Med 1977; 46:1-32.
5. Watanabe Duffy KN, Duffy CM, Gladman DD. Infection and disease activity in systemic lupus erythematosus: a review of hospitalised patients. J Rheumatol 1991; 18:1180-4.
6. Oh HML, Chng HH, Boey ML, Feng PH. Infections in systemic lupus erythematosus. Singapore Med J 1993; 34:406-8.
7. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-7.
8. Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine 1989; 68:141-50.
9. Hellman DB, Petri M, Whiting-O'Keefe Q. Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine 1987; 66:341-8.
10. Liam CK, Wang F. Pneumocystis carinii pneumonia in patients with systemic lupus erythematosus. Lupus 1992; 1:379-85.
11. Kimberley RP. Pulse methylprednisolone in SLE. Clinics Rheum Dis 1982; 8:261-78.
12. Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992; 340:741-5.
13. Austin HA, Klippel JH, Balow JE, le Riche NGH, Steinberg AD, Plotz PH, Decker JL. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314:614-19.
14. Nived O, Sturfelt G, Wollheim F. Systemic lupus erythematosus and infection: a controlled and prospective study including an epidemiological group. Q J Med 1985; 55:271-87.